Screener
Heartflow, Inc. HTFL Accrued Clinical Trial Expenses Current
Accrued Clinical Trial Expenses Current at other companies
Other financials
Where this comes from
Reported directly by Heartflow, Inc. in its filing.
Tagged under the XBRL concept htfl:AccruedClinicalTrialExpensesCurrent.
The source filing: Heartflow, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001464521-26-000071
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued payroll and related expenses | $19,762 | $28,150 |
| Customer contract and rebate liabilities | 1,583 | 1,162 |
| Accrued royalty | 1,049 | 864 |
| Accrued professional fees | 821 | 627 |
| Accrued clinical trial expenses | 1,118 | 550 |
| Other | 1,553 | 1,926 |
| $25,886 | $33,279 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Heartflow, Inc.'s accrued clinical trial expenses current?
- Heartflow, Inc. (HTFL) reported accrued clinical trial expenses current of $1.12M in Q1 2026.
- What does accrued clinical trial expenses current mean?
- Represents the estimated costs incurred for clinical research activities that have not yet been invoiced or paid by the company. This metric is vital for R&D-intensive companies to track the true burn rate and financial commitment to ongoing trials. It provides a more accurate picture of current liabilities than cash outflows alone.
Ask your AI about Heartflow, Inc.'s accrued clinical trial expenses current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude